@Hadrian
The key point is that the very purpose of generics is to circumvent the high prices of branded product, which are caused by the dysfunctional incentives of the middle-men. So what sense would it make to have them held hostage to those channels? More to the point, what incentive would those middle-men have to push low priced generics?
- Forums
- ASX - By Stock
- ACR
- Ann: Launch of Dapsone 5%, Gel in the United States
Ann: Launch of Dapsone 5%, Gel in the United States, page-26
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
|
|||||
Last
6.7¢ |
Change
0.004(6.35%) |
Mkt cap ! $19.18M |
Open | High | Low | Value | Volume |
6.5¢ | 6.7¢ | 6.5¢ | $457 | 7.007K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 46430 | 6.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.8¢ | 563 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 46516 | 0.067 |
2 | 129445 | 0.066 |
2 | 28407 | 0.065 |
1 | 123229 | 0.064 |
2 | 28791 | 0.063 |
Price($) | Vol. | No. |
---|---|---|
0.068 | 563 | 1 |
0.070 | 235749 | 3 |
0.072 | 47301 | 1 |
0.073 | 30000 | 3 |
0.075 | 149999 | 1 |
Last trade - 14.45pm 19/07/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |